Policy & Regulation
CARsgen Therapeutics names new executive director
3 August 2022 -

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a China-based company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announced on Tuesday that it has named Dr Hua Jiang as its new executive director.

Dr Jiang has around 18 years of working experiences in the field of cancer biotherapy. Presently, she serves as vice president of Early Discovery for CARsgen. She has served as senior director of Immune Cell Research and Development Department, responsible for the research work of Immune Cell Research and Development and Preclinical Pharmacology at CARsgen. She has also served at Shanghai Cancer Institute. She was a professor at Shanghai Cancer Institute and a doctoral supervisor at Shanghai Jiao Tong University School of Medicine.

Dr Zonghai Li, founder, chairman of the board, chief executive officer, and chief scientific officer for CARsgen, added, 'On behalf of the board, I would like to congratulate Dr Jiang to be appointed as the executive director. Dr Jiang has rich experiences in cancer research and product development, particularly in the field of CAR T-cell therapies. As the executive director of the board, Dr Jiang will contribute to the diversity of the board and will continue to help us developing innovative and differentiated CAR T products for cancer patients worldwide.'